FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127384> ?p ?o ?g. }

• W4310127384 endingPage "12724" @default.
• W4310127384 startingPage "12723" @default.
• W4310127384 abstract "Background: Anti-CD30 chimeric antigen receptor (CD30.CAR) T-cell therapy has been studied in heavily pretreated relapsed/refractory (r/r) classic Hodgkin lymphoma (cHL) patients with an objective response rate (ORR) of 62% and complete response (CR) rate of 51% (Ramos et al, JCO, 2020). Despite high response rates, disease progression has been observed, with a 1-year PFS of 36%. The anti-PD-1 antibodies nivolumab and pembrolizumab have both been studied in phase II studies in patients with r/r cHL with ORR ranging between 65-87% and median progression free survival (PFS) ranging from 13-15 months. Limited data is available regarding the clinical benefit of anti-PD-1 therapies following CD30.CAR-T cell therapy and the potential mechanism of response in patients with prior anti-PD-1 exposure. Methods: We followed and analyzed the clinical outcome of 10 patients with r/r HL who progressed after CD30.CAR-T cell therapy at the University of North Carolina at Chapel Hill and subsequently received anti-PD-1 therapy to treat relapsed disease. Clinical responses in follow up were determined per local radiologist assessment. Expansion and persistence of CD30.CAR-T cells in vivo was determined by quantitative PCR from peripheral blood samples. Results: Between October 2016 and November 2019, patients were treated with either CD30.CAR-T cells (9 patients) or CD30.CCR4.CAR-T cells (1 patient) on one of three clinical trials (NCT02690545, NCT02663297, NCT03602157). The median age of patients was 30 years (range, 24-51 years). The median number of prior lines of therapy was 8 (range, 5-16). Eight patients had a prior autologous stem cell transplant, and six patients had a prior allogeneic stem cell transplant. The best response to CAR-T cell therapy was a CR in 5 patients, partial response (PR) in 1 patient, and stable/progressive disease in 4 patients. At the time of progression following CD30.CAR-T cell therapy, patients were offered standard of care anti-PD-1 therapy. Eight patients were treated with nivolumab, and 2 patients were treated with pembrolizumab based on decision of the treating physician. The median time from CAR-T cell therapy to anti-PD-1 therapy was 171 days (range, 56-858 days). Seven of the 10 patients had prior anti-PD-1 exposure before CAR-T cell therapy. All 10 patients had an objective response to anti-PD-1 therapy after CAR-T cells, with a best response of CR in 7 patients and PR in 3 patients. Four of the 6 patients who had a PR to anti-PD-1 therapy prior to CAR-T cell treatment, achieved CR with anti-PD-1 re-challenge afterwards. At the time of the last follow up, 8 patients remain in an ongoing response, lasting over 1 year in 7 and over 3 years in 3 patients. The median PFS was not reached in this cohort (Fig 1A). Five patients stopped anti-PD-1 therapy after CAR-T cell therapy (4 related to toxicity of therapy, 1 for ongoing durable response). At the time of data collection, with a median follow up of 3.6 years (range, 1.7-4.7 years), all patients were still alive. Longitudinal peripheral blood samples were available in 3 of the 10 patients. All 3 patients with longitudinal samples demonstrated expansion and/or persistence of CD30.CAR-T cells following anti-PD-1 therapy (Fig 1B). Patient #9 and #5 had impressive expansion of CD30.CAR-T cell signals shortly after start of anti-PD-1 therapy. Patient #1 had detectable PCR signals in the peripheral blood until at least 1 year after CD30.CAR-T cell infusion; however, sample timepoints were not available to assess for expansion of CD30.CAR-T cell signals shortly after anti-PD-1 therapy. Conclusion: To our knowledge, this is the largest cohort of patients with r/r cHL who have received anti-PD-1 therapies after CD30.CAR-T cell treatment. Clinical efficacy appears strong, with high response rates and durable remissions observed even if most patients had prior exposure to anti-PD-1 therapy. All patients with no prior anti-PD-1 exposure experienced durable remissions. This study is the first to describe CD30.CAR-T expansion following anti-PD-1 therapy. While further analysis is warranted to assess for CD30.CAR-T functionality after anti-PD-1 exposure, our data suggest that anti-PD-1 therapy may rescue CD30.CAR T cells, supporting further investigations in patients with cHL. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127384 created "2022-11-30" @default.
• W4310127384 creator A5018029727 @default.
• W4310127384 creator A5026510629 @default.
• W4310127384 creator A5031776733 @default.
• W4310127384 creator A5035811418 @default.
• W4310127384 creator A5053627919 @default.
• W4310127384 creator A5056402774 @default.
• W4310127384 creator A5065544223 @default.
• W4310127384 creator A5075085884 @default.
• W4310127384 creator A5077127349 @default.
• W4310127384 creator A5085820043 @default.
• W4310127384 creator A5086211539 @default.
• W4310127384 creator A5091401985 @default.
• W4310127384 date "2022-11-15" @default.
• W4310127384 modified "2023-10-17" @default.
• W4310127384 title "Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma" @default.
• W4310127384 doi "https://doi.org/10.1182/blood-2022-156660" @default.
• W4310127384 hasPublicationYear "2022" @default.
• W4310127384 type Work @default.
• W4310127384 citedByCount "0" @default.
• W4310127384 crossrefType "journal-article" @default.
• W4310127384 hasAuthorship W4310127384A5018029727 @default.
• W4310127384 hasAuthorship W4310127384A5026510629 @default.
• W4310127384 hasAuthorship W4310127384A5031776733 @default.
• W4310127384 hasAuthorship W4310127384A5035811418 @default.
• W4310127384 hasAuthorship W4310127384A5053627919 @default.
• W4310127384 hasAuthorship W4310127384A5056402774 @default.
• W4310127384 hasAuthorship W4310127384A5065544223 @default.
• W4310127384 hasAuthorship W4310127384A5075085884 @default.
• W4310127384 hasAuthorship W4310127384A5077127349 @default.
• W4310127384 hasAuthorship W4310127384A5085820043 @default.
• W4310127384 hasAuthorship W4310127384A5086211539 @default.
• W4310127384 hasAuthorship W4310127384A5091401985 @default.
• W4310127384 hasBestOaLocation W43101273841 @default.
• W4310127384 hasConcept C121608353 @default.
• W4310127384 hasConcept C126322002 @default.
• W4310127384 hasConcept C143998085 @default.
• W4310127384 hasConcept C2777701055 @default.
• W4310127384 hasConcept C2779338263 @default.
• W4310127384 hasConcept C2911194787 @default.
• W4310127384 hasConcept C2992779791 @default.
• W4310127384 hasConcept C3875195 @default.
• W4310127384 hasConcept C70905583 @default.
• W4310127384 hasConcept C71924100 @default.
• W4310127384 hasConceptScore W4310127384C121608353 @default.
• W4310127384 hasConceptScore W4310127384C126322002 @default.
• W4310127384 hasConceptScore W4310127384C143998085 @default.
• W4310127384 hasConceptScore W4310127384C2777701055 @default.
• W4310127384 hasConceptScore W4310127384C2779338263 @default.
• W4310127384 hasConceptScore W4310127384C2911194787 @default.
• W4310127384 hasConceptScore W4310127384C2992779791 @default.
• W4310127384 hasConceptScore W4310127384C3875195 @default.
• W4310127384 hasConceptScore W4310127384C70905583 @default.
• W4310127384 hasConceptScore W4310127384C71924100 @default.
• W4310127384 hasIssue "Supplement 1" @default.
• W4310127384 hasLocation W43101273841 @default.
• W4310127384 hasOpenAccess W4310127384 @default.
• W4310127384 hasPrimaryLocation W43101273841 @default.
• W4310127384 hasRelatedWork W1970983568 @default.
• W4310127384 hasRelatedWork W201753987 @default.
• W4310127384 hasRelatedWork W2036524875 @default.
• W4310127384 hasRelatedWork W2112022129 @default.
• W4310127384 hasRelatedWork W2390594422 @default.
• W4310127384 hasRelatedWork W2393780027 @default.
• W4310127384 hasRelatedWork W2411077793 @default.
• W4310127384 hasRelatedWork W2947894993 @default.
• W4310127384 hasRelatedWork W2981634038 @default.
• W4310127384 hasRelatedWork W4312094892 @default.
• W4310127384 hasVolume "140" @default.
• W4310127384 isParatext "false" @default.
• W4310127384 isRetracted "false" @default.
• W4310127384 workType "article" @default.